TELOTelomir Pharmaceuticals, Inc.Not started yet
Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)
Triple-Negative Breast Cancer (TNBC) · Advanced Triple-Negative Breast Cancer · Metastatic Triple-negative Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 76 (planned)
- Started
- Oct 2026
- Main results expected
- May 2027
- Fully finished
- Nov 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Phase I: Incidence of Serious Adverse Events (SAEs) and incidence and severity of Treatment-Emergent AEs (TEAEs)
Measured over: From first dose up to approximately 6 months
Phase II: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST)
Measured over: From first recommended dose up to 4 months.
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07581314 · record last updated 2026-06-23 · checked 2026-11-09 15:47 UTC